Eagle Pharmaceuticals (EGRX) Competitors $3.00 +0.11 (+3.63%) As of 07/3/2025 09:30 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EGRX vs. BIOA, CGEN, ALEC, GALT, ACOG, IKT, ALTS, KYTX, RAPT, and LXEOShould you be buying Eagle Pharmaceuticals stock or one of its competitors? The main competitors of Eagle Pharmaceuticals include BioAge Labs (BIOA), Compugen (CGEN), Alector (ALEC), Galectin Therapeutics (GALT), Alpha Cognition (ACOG), Inhibikase Therapeutics (IKT), ALT5 Sigma (ALTS), Kyverna Therapeutics (KYTX), Rapt Therapeutics (RAPT), and Lexeo Therapeutics (LXEO). These companies are all part of the "pharmaceutical products" industry. Eagle Pharmaceuticals vs. Its Competitors BioAge Labs Compugen Alector Galectin Therapeutics Alpha Cognition Inhibikase Therapeutics ALT5 Sigma Kyverna Therapeutics Rapt Therapeutics Lexeo Therapeutics BioAge Labs (NASDAQ:BIOA) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings. Do insiders & institutionals hold more shares of BIOA or EGRX? 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 20.8% of BioAge Labs shares are held by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to BIOA or EGRX? In the previous week, BioAge Labs had 2 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 2 mentions for BioAge Labs and 0 mentions for Eagle Pharmaceuticals. Eagle Pharmaceuticals' average media sentiment score of 0.00 beat BioAge Labs' score of -0.17 indicating that Eagle Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment BioAge Labs Neutral Eagle Pharmaceuticals Neutral Is BIOA or EGRX more profitable? Company Net Margins Return on Equity Return on Assets BioAge LabsN/A N/A N/A Eagle Pharmaceuticals N/A N/A N/A Which has better valuation & earnings, BIOA or EGRX? Eagle Pharmaceuticals has higher revenue and earnings than BioAge Labs. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAge LabsN/AN/A-$71.11MN/AN/AEagle Pharmaceuticals$257.55M0.15$35.64MN/AN/A SummaryEagle Pharmaceuticals beats BioAge Labs on 5 of the 6 factors compared between the two stocks. Get Eagle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EGRX vs. The Competition Export to ExcelMetricEagle PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.96M$784.80M$5.53B$9.03BDividend YieldN/A4.84%5.24%4.01%P/E RatioN/A1.0919.3119.89Price / Sales0.15230.50424.59117.07Price / Cash0.4023.4426.2128.59Price / BookN/A6.237.925.55Net Income$35.64M-$27.94M$3.17B$248.49M7 Day Performance3.45%2.21%2.18%5.37%1 Month Performance33.33%8.98%1.25%6.63%1 Year Performance-45.45%11.57%33.90%21.20% Eagle Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EGRXEagle PharmaceuticalsN/A$3.00+3.6%N/A-45.5%$38.96M$257.55M0.00100Gap DownBIOABioAge LabsN/A$4.13-1.7%N/AN/A$150.57MN/A0.00N/ACGENCompugen1.5238 of 5 stars$1.78+7.2%$4.00+124.7%+14.1%$148.13M$27.86M-11.1370Positive NewsALECAlector3.7977 of 5 stars$1.40-5.4%$4.00+185.7%-66.4%$147.99M$100.56M-1.11270GALTGalectin Therapeutics1.6317 of 5 stars$2.11-9.4%$6.00+184.4%+4.6%$147.47MN/A-2.939Gap UpACOGAlpha Cognition1.6643 of 5 stars$9.33+2.5%$20.00+114.4%N/A$145.86MN/A-7.77N/AGap UpIKTInhibikase Therapeutics1.3436 of 5 stars$1.95+20.4%$6.50+233.3%+62.9%$144.97M$260K-0.736ALTSALT5 Sigma0.0587 of 5 stars$7.24-10.9%N/AN/A$141.91M$12.53M0.00170KYTXKyverna Therapeutics1.2685 of 5 stars$3.07-6.4%$18.50+502.6%-58.7%$141.76M$7.03M-0.9196RAPTRapt Therapeutics4.1986 of 5 stars$8.00-5.1%$24.00+200.0%-63.7%$139.40M$1.53M-0.4280LXEOLexeo Therapeutics1.8733 of 5 stars$4.02-2.4%$16.60+312.9%-71.4%$136.77M$650K-1.2258News CoverageGap Up Related Companies and Tools Related Companies BIOA Alternatives CGEN Alternatives ALEC Alternatives GALT Alternatives ACOG Alternatives IKT Alternatives ALTS Alternatives KYTX Alternatives RAPT Alternatives LXEO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EGRX) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
